DrugsHumansDiabetes MellitusType 2ObesityDrug Approval
Mazdutide: First Approval.
Matt Shirley
Published: 202510.1007/s40265-025-02249-y
Abstract
Mazdutide (Xinermei®) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight an…
Preview only. Read the full abstract at the source